Premium
Hidradenitis suppurativa and polycystic ovarian syndrome: Systematic review and meta‐analysis
Author(s) -
Phan Kevin,
Charlton Olivia,
Smith Saxon D
Publication year - 2020
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.13110
Subject(s) - hidradenitis suppurativa , medicine , hyperandrogenism , meta analysis , polycystic ovary , dermatology , odds ratio , observational study , disease , obesity , insulin resistance
Background/Objectives Hidradenitis suppurativa has been associated with a number of pathologies, including various endocrine and autoimmune disorders. Although signs of hyperandrogenism are common in hidradenitis suppurativa, few formal studies have assessed the relationship between hidradenitis suppurativa and polycystic ovarian syndrome. Therefore, we performed a systematic review and meta‐analysis to assess the association between hidradenitis suppurativa and polycystic ovarian syndrome. Methods We performed a systematic review and meta‐analysis according to PRISMA guidelines. Odds ratio was used as the effect size, with random‐effects meta‐analysis. Results We identified five case‐control studies for inclusion. From pooled data, we found a significantly higher proportion of polycystic ovarian syndrome in hidradenitis suppurativa cases compared with controls ( OR 2.64; 95% CI 1.69–4.11; P < 0.00001). There was significant heterogeneity noted ( I 2 = 88%, P < 0.00001). Limitations included that studies reviewed were observational by design which are susceptible to bias, and lack of randomisation. Conclusions In summary, pooled analysis of existing case‐control studies supports a significant association between hidradenitis suppurativa and polycystic ovarian syndrome. Our results imply that hidradenitis suppurativa patients with signs of hyperandrogenism may benefit from screening for polycystic ovarian syndrome, and may potentially benefit from anti‐androgen therapy.